CR8537A - Moduladores de HM74 de Oxidecahidronaftaleno - Google Patents

Moduladores de HM74 de Oxidecahidronaftaleno

Info

Publication number
CR8537A
CR8537A CR8537A CR8537A CR8537A CR 8537 A CR8537 A CR 8537A CR 8537 A CR8537 A CR 8537A CR 8537 A CR8537 A CR 8537A CR 8537 A CR8537 A CR 8537A
Authority
CR
Costa Rica
Prior art keywords
oxidecahydronaphthalene
modulators
oxidecalin
molecules
host cells
Prior art date
Application number
CR8537A
Other languages
English (en)
Inventor
Minnich Anne
Kuntzeiler Theresa
Elshingdrelo Haifeng
Angelastro Michael
Henke Stepahn
Original Assignee
Aventis Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Inc filed Critical Aventis Pharma Inc
Publication of CR8537A publication Critical patent/CR8537A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pyrrole Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pyrane Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Steroid Compounds (AREA)

Abstract

Se usaron celulas hospedantes que expresan HM74 para obtener moleculas de tipo oxidecalina con actividad agonista, que tienen la formula estructural que se indica.
CR8537A 2004-02-20 2006-07-26 Moduladores de HM74 de Oxidecahidronaftaleno CR8537A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US54601204P 2004-02-20 2004-02-20

Publications (1)

Publication Number Publication Date
CR8537A true CR8537A (es) 2007-03-05

Family

ID=34910747

Family Applications (1)

Application Number Title Priority Date Filing Date
CR8537A CR8537A (es) 2004-02-20 2006-07-26 Moduladores de HM74 de Oxidecahidronaftaleno

Country Status (21)

Country Link
US (2) US7264937B2 (es)
EP (1) EP1718293A1 (es)
JP (1) JP2007526917A (es)
KR (1) KR101145693B1 (es)
CN (1) CN1929833A (es)
AR (1) AR047708A1 (es)
AU (1) AU2005216878B2 (es)
BR (1) BRPI0507916A (es)
CA (1) CA2556757C (es)
CR (1) CR8537A (es)
EC (1) ECSP066776A (es)
IL (1) IL177106A (es)
MA (1) MA28368A1 (es)
ME (2) MEP17008A (es)
NO (1) NO20064214L (es)
RS (1) RS20060472A (es)
RU (1) RU2006133539A (es)
TN (1) TNSN06235A1 (es)
TW (1) TWI354552B (es)
WO (1) WO2005082352A1 (es)
ZA (1) ZA200606687B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1603585A2 (en) * 2003-03-14 2005-12-14 Bristol-Myers Squibb Company Polynucleotide encoding a novel human g-protein coupled receptor variant of hm74, hgprbmy74
NZ555320A (en) 2004-12-03 2010-11-26 Schering Corp Substituted piperazines as CB1 antagonists
CA2637565A1 (en) * 2006-01-18 2007-07-26 Schering Corporation Cannibinoid receptor modulators
US20100197564A1 (en) * 2007-04-19 2010-08-05 Schering Corporation Diaryl morpholines as cb1 modulators
EP2548874A3 (en) * 2007-06-28 2013-05-15 Intervet International B.V. Substituted piperazines as CB1 antagonists
JP2010531874A (ja) * 2007-06-28 2010-09-30 インターベット インターナショナル ベー． フェー． Ｃｂ１アンタゴニストとしての置換ピペラジン

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) * 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5674908A (en) * 1993-12-20 1997-10-07 Life Technologies, Inc. Highly packed polycationic ammonium, sulfonium and phosphonium lipids
DE19624154A1 (de) 1996-06-18 1998-01-08 Hoechst Ag Ringannelierte Dihydropyrane, Verfahren zur Herstellung sowie deren Verwendung
US6555339B1 (en) 1997-04-14 2003-04-29 Arena Pharmaceuticals, Inc. Non-endogenous, constitutively activated human protein-coupled receptors
EP1007563A4 (en) * 1997-06-12 2003-04-16 Smithkline Beecham Corp HM74A RECEPTOR
GB0021484D0 (en) * 2000-09-01 2000-10-18 Boehringer Ingelheim Pharma Method for identifying substances which positively influence inflammatory conditions of chronic inflammatory airway diseases

Also Published As

Publication number Publication date
IL177106A0 (en) 2006-12-10
ZA200606687B (en) 2008-02-27
TWI354552B (en) 2011-12-21
JP2007526917A (ja) 2007-09-20
TW200539864A (en) 2005-12-16
MEP17008A (en) 2010-06-10
IL177106A (en) 2012-03-29
RS20060472A (en) 2008-11-28
RU2006133539A (ru) 2008-03-27
ME00059B (me) 2010-06-10
TNSN06235A1 (en) 2007-12-03
AU2005216878A1 (en) 2005-09-09
ECSP066776A (es) 2006-11-16
BRPI0507916A (pt) 2007-07-10
CA2556757C (en) 2011-05-03
US20080045586A1 (en) 2008-02-21
MA28368A1 (fr) 2006-12-01
CN1929833A (zh) 2007-03-14
US20050187263A1 (en) 2005-08-25
CA2556757A1 (en) 2005-09-09
US7264937B2 (en) 2007-09-04
KR101145693B1 (ko) 2012-05-25
EP1718293A1 (en) 2006-11-08
WO2005082352A1 (en) 2005-09-09
AR047708A1 (es) 2006-02-08
KR20060127982A (ko) 2006-12-13
AU2005216878B2 (en) 2010-06-17
NO20064214L (no) 2006-09-18

Similar Documents

Publication Publication Date Title
BRPI0811993A2 (pt) " hetarilanilinas como moduladores para beta-amiloide ".
BRPI0814593A2 (pt) Composto, composição farmacêutica que o contém e uso do composto.
GT200600112A (es) Composiciiones de tigeciclina y metodos de preparacion
BRPI0817475A2 (pt) meio legível por computador.
BRPI0810744A2 (pt) Moléculas absorventes de oxigênio, objetos que as contêm, e métodos de sua utilização
BRPI1011886A2 (pt) solução contendo ácido hiplocloroso e métodos do uso do mesmo.
CL2008001656A1 (es) Anticuerpo anti-c3b; composicion farmaceutica que lo comprende, y su uso para prevenir o tratar un trastorno asociado con el complemento; kit que lo contiene.
ECSP088461A (es) Composiciones farmacéuticas que contienen buprenorfina
CR11548A (es) Azolilmetiloxiranos, su uso y agentes que los contienen
CR10075A (es) Bifenilcarboxamidas para combatir microorganismos.
CR9786A (es) Compuestos de bencimidazol-tiofeno
CL2007002971A1 (es) Compuestos derivados de aminometil-4-imidazol; procedimiento de preparacion; composicion farmaceutica que los contiene; y su uso para tratar depresion, ansiedad, trastorno bipolar, entre otras.
CR8528A (es) Derivados de furosemida como moduladores de hm74 y su uso para el tratamiento de la inflamacion
DE502005003251D1 (de) Verwendung von menadione zur verstärkung der wirksamkeit von agrochemikalien
CL2008002041A1 (es) Compuestos derivados de piperidina; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar ansiedad.
CL2008001393A1 (es) Compuestos derivados de dihidroquinonas y dihidronaftiridinas, inhibidores de jnk; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar artritis reumatoide, asma, diabetes tipo 2, alzheimer, enfermedad de parkinson, hiperproliferacion celular.
CL2007002970A1 (es) Compuestos derivados de aminometil-4-imidazol; procedimiento de preparacion; composicion farmaceutica que los contiene; y su uso para tratar depresion, ansiedad, trastorno bipolar, entre otras.
CR8537A (es) Moduladores de HM74 de Oxidecahidronaftaleno
CL2011000268A1 (es) Uso de dronedarona para preparar un medicamento util en la prevencion del ictus o ataque isquemico transitorio.
PA8845301A1 (es) Polipéptidos que tienen actividad antimicrobiana
AR055394A1 (es) Polipeptidos con actividad antimicrobiana y polinucleotidos que los codifican
AR052947A1 (es) Polipeptidos que tienen actividad antimicrobiana y polinucleotidos que codifican para los mismos
AR073871A1 (es) Intermediario de fulvestran
EA201000864A1 (ru) Фенилоксетанильные производные
BRPI0907797A2 (pt) Novo uso de 3,3'-diindolimetano

Legal Events

Date Code Title Description
FC Refusal